Trials / Terminated
TerminatedNCT02976766
Gypenosides Treatment for Optic Neuritis
Gypenosides Treatment for Optic Neuritis: a Randomised, Double-blind, Placebo-controlled Trial
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- First Affiliated Hospital of Guangxi Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether gypenosides are neuroprotective in patients with acute optic neuritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gypenosides | Participants will receive gypenosides 180 mg/day (60 mg three times a day) for 10 days. |
| DRUG | Placebo | Participants will receive placebo three times a day for 10 days. |
Timeline
- Start date
- 2017-02-04
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
- First posted
- 2016-11-29
- Last updated
- 2025-12-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02976766. Inclusion in this directory is not an endorsement.